# ENGNW (enGene Therapeutics Inc.) - SEC EDGAR Financial Statements

> enGene Therapeutics Inc. reported $288.3M in total assets and a net loss of $130.4M through October 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/ENGNW
- Markdown: https://convexityos.com/fundamentals/ENGNW.md
- SEC CIK: 0001980845
- Reporting currency: USD
- Latest filing period: July 31, 2026
- Last synced: Nov 20, 2026, 05:48 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001980845&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Oct 31, 2025 |
| Operating Income | FY 2025 | -$136.6M | Operating profit |
| Net Income | FY 2025 | -$130.4M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$1.87 | Split-adjusted |
| Free Cash Flow | FY 2025 | -$104.0M | Operating CF less CapEx |
| Cash & ST Investments | Jul 31, 2026 | $266.3M | Total debt: $7.92M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Research & Development | $94.48M | $38.31M | $16.46M | $15.47M |
| Total Operating Expenses | $123.2M | $62.30M | $26.06M | $19.43M |
| **Operating Income** | -$123.2M | -$62.30M | -$26.06M | -$19.43M |
| **EBITDA** | -$122.7M | -$62.00M | -$25.86M | -$19.23M |
| Interest Income | $9.43M | $10.41M | $1.12M | $129K |
| Interest Expense | $2.99M | $2.80M | $4.95M | $1.42M |
| Income Before Tax | -$117.3M | -$55.16M | -$99.90M | -$24.44M |
| Income Tax Expense | $0 | -$19K | $17K | $22K |
| **Net Income** | -$117.3M | -$55.14M | -$99.92M | -$24.46M |
| Basic EPS | $2.29 | $1.46 | $151.22 | $44.30 |
| **Diluted EPS** | $2.29 | $1.46 | $151.22 | $44.30 |
| Basic Shares Outstanding | 51.1M | 37.8M | 692.6K | 655.2K |
| Diluted Shares Outstanding | 51.1M | 37.8M | 692.6K | 655.2K |

### Income Statement (Quarterly)

| Line Item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $20.09M | $22.20M | $22.25M | $31.72M | $22.57M | $20.21M | $19.97M | $11.27M |
| Total Operating Expenses | $34.01M | $31.97M | $31.18M | $39.48M | $29.95M | $27.12M | $26.61M | $17.45M |
| **Operating Income** | -$34.01M | -$31.97M | -$31.18M | -$39.48M | -$29.95M | -$27.12M | -$26.61M | -$17.45M |
| **EBITDA** | -$33.91M | -$31.77M | -$31.00M | -$39.28M | -$29.85M | -$27.02M | -$26.51M | -$17.36M |
| Interest Income | $2.40M | $2.66M | $2.74M | $1.98M | $2.23M | $2.49M | $2.73M | $3.02M |
| Interest Expense | $843K | $745K | $732K | $750K | $758K | $734K | $752K | $756K |
| Income Before Tax | -$32.50M | -$30.23M | -$29.75M | -$38.38M | -$28.75M | -$25.57M | -$24.60M | -$15.28M |
| Income Tax Expense | $0 | $0 | $0 | -$497K | $239K | $240K | $18K | $19K |
| **Net Income** | -$32.50M | -$30.23M | -$29.75M | -$37.88M | -$28.99M | -$25.82M | -$24.62M | -$15.30M |
| Basic EPS | -$0.47 | -$0.43 | $0.44 | -- | -$0.57 | -$0.51 | $0.48 | -- |
| **Diluted EPS** | -$0.47 | -$0.43 | $0.44 | -- | -$0.57 | -$0.51 | $0.48 | -- |
| Basic Shares Outstanding | 69.7M | 69.7M | 67.3M | -- | 51.1M | 51.0M | 51.0M | -- |
| Diluted Shares Outstanding | 69.7M | 69.7M | 67.3M | -- | 51.1M | 51.0M | 51.0M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $50.15M | $173.0M | $81.52M | $20.43M |
| Short-Term Investments | $143.6M | $65.33M | -- | -- |
| **Cash & Short-Term Investments** | $193.7M | $238.3M | $81.52M | $20.43M |
| **Total Current Assets** | $201.4M | $247.4M | $85.44M | $22.58M |
| Property, Plant & Equipment, Net | $2.48M | $1.17M | $589K | $387K |
| Long-Term Investments | $8.52M | $59.53M | -- | -- |
| Other Non-Current Assets | $1.36M | $1.37M | $930K | $939K |
| **Total Non-Current Assets** | $20.08M | $63.81M | $1.52M | $1.33M |
| **Total Assets** | $221.5M | $311.2M | $86.96M | $23.91M |
| Accounts Payable | $6.69M | $1.41M | $1.16M | $723K |
| **Total Current Liabilities** | $31.98M | $14.66M | $5.26M | $5.10M |
| **Total Non-Current Liabilities** | $21.78M | $23.90M | $9.22M | $42.30M |
| **Total Liabilities** | $53.76M | $38.56M | $14.47M | $47.41M |
| **Total Debt (incl. Leases)** | $8.47M | $1.80M | -- | -- |
| Common Stock | $513.3M | $509.8M | $259.4M | $16.39M |
| Retained Earnings | -$372.0M | -$254.7M | -$199.6M | -$99.67M |
| Accumulated Other Comp. Income | -$888K | -$1.42M | -$1.02M | -$1.02M |
| **Total Stockholders' Equity** | $167.7M | $272.6M | $72.49M | -$76.61M |
| Total Equity | $167.7M | $272.6M | $72.49M | -$76.61M |

### Balance Sheet (Quarterly)

| Line Item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $41.02M | $29.83M | $36.61M | $50.15M | $32.62M | $57.55M | $62.35M | $173.0M |
| Short-Term Investments | $225.3M | $228.6M | $239.3M | $143.6M | $169.3M | $159.8M | $151.5M | $65.33M |
| **Cash & Short-Term Investments** | $266.3M | $258.5M | $275.9M | $193.7M | $201.9M | $217.4M | $213.8M | $238.3M |
| **Total Current Assets** | $277.9M | $270.0M | $289.2M | $201.4M | $211.3M | $228.0M | $222.3M | $247.4M |
| Property, Plant & Equipment, Net | $2.16M | $2.33M | $2.44M | $2.48M | $1.88M | $1.55M | $1.37M | $1.17M |
| Long-Term Investments | $0 | $26.71M | $36.60M | $8.52M | $23.01M | $34.11M | $58.98M | $59.53M |
| Other Non-Current Assets | $1.39M | $1.38M | $1.39M | $1.36M | $1.38M | $1.38M | $1.58M | $1.37M |
| **Total Non-Current Assets** | $10.42M | $37.52M | $47.90M | $20.08M | $34.24M | $38.68M | $63.61M | $63.81M |
| **Total Assets** | $288.3M | $307.5M | $337.1M | $221.5M | $245.6M | $266.7M | $285.9M | $311.2M |
| Accounts Payable | $2.54M | $1.79M | $2.44M | $6.69M | $2.38M | $1.57M | $2.60M | $1.41M |
| **Total Current Liabilities** | $27.21M | $21.48M | $24.61M | $31.98M | $20.44M | $18.00M | $12.96M | $14.66M |
| **Total Non-Current Liabilities** | $30.82M | $30.87M | $30.96M | $21.78M | $24.44M | $21.36M | $23.03M | $23.90M |
| **Total Liabilities** | $58.03M | $52.36M | $55.57M | $53.76M | $44.88M | $39.36M | $35.98M | $38.56M |
| **Total Debt (incl. Leases)** | $7.92M | $8.25M | $8.54M | $8.47M | $8.26M | $1.77M | $1.75M | $1.80M |
| Common Stock | $632.0M | $632.0M | $632.0M | $513.3M | $510.2M | $510.1M | $509.8M | $509.8M |
| Retained Earnings | -$464.5M | -$432.0M | -$401.8M | -$372.0M | -$334.2M | -$305.2M | -$279.3M | -$254.7M |
| Accumulated Other Comp. Income | -$1.35M | -$1.14M | -$842K | -$888K | -$1.21M | -$969K | -$1.27M | -$1.42M |
| **Total Stockholders' Equity** | $230.3M | $255.2M | $281.5M | $167.7M | $200.7M | $227.3M | $249.9M | $272.6M |
| Total Equity | $230.3M | $255.2M | $281.5M | $167.7M | $200.7M | $227.3M | $249.9M | $272.6M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Net Income | -$117.3M | -$55.14M | -$99.92M | -$24.46M |
| Depreciation & Amortization | $500K | $300K | $200K | $200K |
| Stock-Based Compensation | $9.65M | $5.32M | $3.45M | $116K |
| Change in Payables | $4.94M | $474K | $373K | -$197K |
| **Operating Cash Flow** | -$99.24M | -$48.28M | -$24.74M | -$17.59M |
| Capital Expenditure | -$1.49M | -$925K | -$318K | -$153K |
| **Free Cash Flow** | -$100.7M | -$49.21M | -$25.06M | -$17.75M |
| Purchases of Investments | -$160.8M | -$125.0M | -- | -- |
| **Investing Cash Flow** | -$25.14M | -$126.0M | -$318K | -$153K |
| Common Stock Issued | -- | -- | $56.89M | -- |
| Dividends Paid | -- | -- | $0 | -- |
| **Financing Cash Flow** | $1.52M | $265.7M | $86.15M | $27.97M |
| **Net Change in Cash** | -$122.9M | $91.48M | $61.09M | $9.42M |

### Cash Flow Statement (Quarterly)

| Line Item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$32.50M | -$30.23M | -$29.75M | -$37.88M | -$28.99M | -$25.82M | -$24.62M | -$15.30M |
| Depreciation & Amortization | $100K | $200K | $189K | $200K | $100K | $100K | $102K | $100K |
| Stock-Based Compensation | $7.81M | $4.14M | $2.80M | $2.61M | $2.58M | $2.65M | $1.81M | $1.66M |
| Change in Payables | $744K | -$625K | -$4.27M | $3.97M | $818K | -$974K | $1.13M | -$1.45M |
| **Operating Cash Flow** | -$18.95M | -$30.50M | -$28.90M | -$24.96M | -$25.63M | -$22.95M | -$25.70M | -$19.57M |
| Capital Expenditure | $0 | -$98K | -$153K | -$437K | -$704K | -$45K | -$299K | -$238K |
| **Free Cash Flow** | -$18.95M | -$30.60M | -$29.06M | -$25.40M | -$26.34M | -$22.99M | -$26.00M | -$19.81M |
| Purchases of Investments | -$42.38M | -$50.21M | -$169.2M | -$7.75M | -$44.67M | -$13.76M | -$94.67M | -- |
| **Investing Cash Flow** | $30.12M | $23.64M | -$126.3M | $40.50M | $1.38M | $17.95M | -$84.96M | -$125.3M |
| **Financing Cash Flow** | $23K | $74K | $141.7M | $1.99M | -$667K | $199K | $1.0K | $60.16M |
| **Net Change in Cash** | $11.20M | -$6.79M | -$13.54M | $17.53M | -$24.92M | -$4.80M | -$110.7M | -$84.67M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -69.9% | -20.2% | -137.8% | -- |
| Return on Assets (ROA) | -53.0% | -17.7% | -114.9% | -102.3% |
| Current Ratio | 6.30x | 16.87x | 16.25x | 4.42x |
| Quick Ratio | 6.06x | 16.26x | 15.51x | 4.00x |
| Debt to Equity | 0.05x | 0.01x | -- | -- |
| EPS Growth (YoY) | +56.8% | -99.0% | +241.4% | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -56.6% | -49.7% | -43.5% | -69.9% | -47.2% | -35.1% | -27.6% | -20.2% |
| Return on Assets (ROA) | -45.2% | -41.2% | -36.3% | -53.0% | -38.6% | -30.0% | -24.1% | -17.7% |
| Current Ratio | 10.21x | 12.57x | 11.75x | 6.30x | 10.34x | 12.66x | 17.16x | 16.87x |
| Quick Ratio | 9.79x | 12.03x | 11.21x | 6.06x | 9.88x | 12.08x | 16.50x | 16.26x |
| Debt to Equity | 0.03x | 0.03x | 0.03x | 0.05x | 0.04x | 0.01x | 0.01x | 0.01x |
| EPS Growth (YoY) | -- | -- | -8.3% | -- | -278.1% | -234.2% | +4.3% | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
